ARVN logo

ARVN
Arvinas Inc

1,828
Mkt Cap
$587.14M
Volume
778,422.00
52W High
$14.51
52W Low
$6.06
PE Ratio
-2.79
ARVN Fundamentals
Price
$9.09
Prev Close
$9.10
Open
$9.12
50D MA
$10.46
Beta
1.36
Avg. Volume
757,329.92
EPS (Annual)
-$1.14
P/B
1.52
Rev/Employee
$1.07M
$164.57
Loading...
Loading...
News
all
press releases
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval.read more...
News Placeholder
More News
News Placeholder
RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside?
Rigel Pharmaceuticals signed a global licensing deal with Arvinas and Pfizer for an advanced breast cancer treatment.
News Placeholder
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
Arvinas (ARVN) delivered earnings and revenue surprises of +5.01% and -0.74%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Rigel Pharma Signs Licensing Agreement With Arvinas And Pfizer For Veppanu
(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) on Tuesday said it has entered into a global license agreement with Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) to develop, manufacture and commercialize beast cancer treatment Veppanu...
News Placeholder
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates
Septerna, Inc. (SEPN) delivered earnings and revenue surprises of +63.04% and +32.93%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of +9.09% and +1.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
News Placeholder
HC Wainwright Brokers Reduce Earnings Estimates for Arvinas
Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Equities research analysts at HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for Arvinas in a research report issued to clients and investors on Monday, May 4th. HC Wainwright analyst A. Fein now forecasts that the company will ea...
News Placeholder
Arvinas (NASDAQ:ARVN) Shares Gap Down - Should You Sell?
Arvinas (NASDAQ:ARVN) Shares Gap Down - Time to Sell...
News Placeholder
Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy
Pfizer and Arvinas secure FDA approval for VEPPANU (vepdegestrant), a first-of-its-kind treatment for ESR1-mutated advanced breast cancer.read more...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available